这篇文章不错，转发给_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

中庸之道不偏不倚
2022-03-20

这篇文章不错，转发给大家看

@李秋实医药投资：

口服新冠药物，上游原料药和中间体炒过火了，脱离了基本面的支撑，未来是制剂的长线机会，还是继续看好3CL机制的药物，是我一直强调的。炒作的都会打回原型，基于科学深度研究的投资才能长期胜出。未来1-2年口服药会一步一步从临床，到上市，到为老百姓解决问题。

口服新冠药物，上游原料药和中间体炒过火了，脱离了基本面的支撑，未来是制剂的长线机会，还是继续看好3CL机制的药物，是我一直强调的。炒作的都会打回原型，基于科学深度研究的投资才能长期胜出。未来1-2年口服药会一步一步从临床，到上市，到为老百姓解决问题。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":634770675,"tweetId":"634770675","gmtCreate":1647751351917,"gmtModify":1647751351917,"author":{"id":3513145542725142,"authorId":3513145542725142,"authorIdStr":"3513145542725142","name":"中庸之道不偏不倚","avatar":"https://static.tigerbbs.com/8c0011a44ee17714a9cd49b2cd557a20","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","htmlText":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","text":"这篇文章不错，转发给大家看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/634770675","repostId":634540386,"repostType":1,"repost":{"magic":2,"id":634540386,"tweetId":"634540386","gmtCreate":1647585036841,"gmtModify":1647612199733,"author":{"id":4097915146279240,"authorId":4097915146279240,"authorIdStr":"4097915146279240","name":"李秋实医药投资","avatar":"https://static.tigerbbs.com/1103cc0c6a5fac44564371c1fa44d376","vip":2,"userType":2,"introduction":"熙德博远资本创始合伙人","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[{"themeId":"5f4e0a7185a74ed196abff08008266de","categoryId":"b76d3c59fc044df59779c041b25852a6","name":"分享我的交易策略","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":5f4e0a7185a74ed196abff08008266de}&rnconfig={\"headerBarHidden\": true}","description":"交易策略分享，说一说自己在交易中的那些神操作吧，你的idea说不定价值百万！","image":"https://static.tigerbbs.com/cd8eaff2e99964ab7a80d92cc196fcd3"}],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n口服新冠药物，上游原料药和中间体炒过火了，脱离了基本面的支撑，未来是制剂的长线机会，还是继续看好3CL机制的药物，是我一直强调的。炒作的都会打回原型，基于科学深度研究的投资才能长期胜出。未来1-2年口服药会一步一步从临床，到上市，到为老百姓解决问题。<br></body></html>","htmlText":"<html><head></head><body>\n口服新冠药物，上游原料药和中间体炒过火了，脱离了基本面的支撑，未来是制剂的长线机会，还是继续看好3CL机制的药物，是我一直强调的。炒作的都会打回原型，基于科学深度研究的投资才能长期胜出。未来1-2年口服药会一步一步从临床，到上市，到为老百姓解决问题。<br></body></html>","text":"口服新冠药物，上游原料药和中间体炒过火了，脱离了基本面的支撑，未来是制剂的长线机会，还是继续看好3CL机制的药物，是我一直强调的。炒作的都会打回原型，基于科学深度研究的投资才能长期胜出。未来1-2年口服药会一步一步从临床，到上市，到为老百姓解决问题。","highlighted":2,"essential":2,"paper":1,"link":"https://laohu8.com/post/634540386","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["603883"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":233,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":657,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":25,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}